1. Home
  2. ADIL vs LEXX Comparison

ADIL vs LEXX Comparison

Compare ADIL & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adial Pharmaceuticals Inc

ADIL

Adial Pharmaceuticals Inc

HOLD

Current Price

$5.31

Market Cap

7.3M

Sector

Health Care

ML Signal

HOLD

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

HOLD

Current Price

$10.52

Market Cap

8.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADIL
LEXX
Founded
2010
2004
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.3M
8.7M
IPO Year
2017
2011

Fundamental Metrics

Financial Performance
Metric
ADIL
LEXX
Price
$5.31
$10.52
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$37.50
$1.50
AVG Volume (30 Days)
78.8K
96.9K
Earning Date
05-13-2026
04-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$705,923.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$601.47
P/E Ratio
N/A
N/A
Revenue Growth
N/A
52.05
52 Week Low
$0.13
$0.35
52 Week High
$6.41
$12.89

Technical Indicators

Market Signals
Indicator
ADIL
LEXX
Relative Strength Index (RSI) 62.70 81.60
Support Level $1.73 $0.65
Resistance Level N/A N/A
Average True Range (ATR) 0.70 1.01
MACD 0.13 0.39
Stochastic Oscillator 59.41 67.66

Price Performance

Historical Comparison
ADIL
LEXX

About ADIL Adial Pharmaceuticals Inc

Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its investigational new drug candidate, AD04, is being developed as a therapeutic agent for the treatment of alcohol use disorder. The company operates as one operating segment with a focus on drug development for addiction and related disorders.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: